A novel research partnership in AI to advance drug discovery, longevity & aging research
By a
"I have known and admired Alex for at least 15 years, during which he has pioneered several groundbreaking initiatives that contributed substantially to the anti-aging crusade. Insilico is his most important effort yet, and it is fantastic to see that others, including such major global players as WuXi, share my enthusiasm. Insilico's technological breakthroughs have resulted from having a terrific leader and a wonderful team, and I'm sure that their success will go from strength to strength" said
WuxiApptec offers its clients a diverse and integrated suite of services to assist its global customer base and partners to minimize drug discovery and development time while simultaneously lowering the overall cost of biopharmaceutical and medical device R&D via streamlined and cost-effective solutions. By combining WuxiTec's comprehensive platform and services with Insilico's hallmark expertise in AI for drug discovery and biomarker development, the partnership has the potential to help usher in dramatic paradigm shifts in the drug development process, by focusing on slashing inefficiencies in the preclinical drug design stage of drug development, cutting development time and cost, and accelerating the pace by which lifesaving drugs can be delivered from the lab and into the hands of patients and doctors.
"Insilico Medicine is on the forefront of Artificial Intelligence for aging and longevity research. Its potential to deliver more QALY to nations threatened by demographic aging, and the dire economic burden that it poses in the coming years if not dealt with in terms of shifting from treatment to prevention and from palliative geriatrics toward comprehensive human healthspan extension, cannot be understated. We are proud to salute our CSO on the ongoing progress than his company is forging towards making extended healthy longevity a reality" said
Insilico Medicine work in AI for age-related drug discovery and biomarker development is routinely covered in papers in peer-reviewed journals and major industry conferences. Their work has most recently been covered by MIT Technology Review China, Nature Medicine, Nature Biotechnology,
"I am really pleased that Insilico Medicine has attracted this new investment from such high calibre and internationally recognised partners. As the Insilico board representative of
The announcement of this partnership follows just weeks after the announcement of a partnership between Insilico Medicine and Nebula Genomics (led by renowned geneticist
"Insilico Medicine is on the forefront of applying advanced machine learning and deep learning techniques, including Generative Adversarial Networks (GANs) in particular, to novel molecule generation and target identification for aging research and the extension of healthy longevity. More broadly, the newly announced partnership between Insilico Medicine and
Keywords for this news article include: Machine Learning, Biopharmaceuticals, Drugs and Therapies, Health and Medicine, Emerging Technologies, Investment and Finance, Artificial Intelligence,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
Life Partners Position Holder Trust Files SEC Form 8-K, Current Report: (Jun. 19, 2018)
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News